2009
DOI: 10.1200/jco.2008.20.1293
|View full text |Cite
|
Sign up to set email alerts
|

Abstract: A B S T R A C T PurposeA randomized, phase III trial demonstrated superiority of sunitinib over interferon alfa (IFN-␣) in progression-free survival (primary end point) as first-line treatment for metastatic renal cell carcinoma (RCC). Final survival analyses and updated results are reported. Patients and MethodsSeven hundred fifty treatment-naïve patients with metastatic clear cell RCC were randomly assigned to sunitinib 50 mg orally once daily on a 4 weeks on, 2 weeks off dosing schedule or to IFN-␣ 9 MU sub… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

71
1,499
12
50

Year Published

2010
2010
2021
2021

Publication Types

Select...
10

Relationship

0
10

Authors

Journals

citations
Cited by 1,986 publications
(1,632 citation statements)
references
References 11 publications
71
1,499
12
50
Order By: Relevance
“…Indeed sunitinib monotherapy doubles progression-free survival and extends overall survival in this disease and is now standard first-line therapy (Motzer et al, 2007(Motzer et al, , 2009. Despite these impressive results, variation in response between individuals occurs and, more importantly, resistance to therapy invariably develops (Motzer et al, 2009;Rini and Atkins, 2009). Determinants of sunitinib response and the mechanisms that mediate the onset of resistance to sunitinib are poorly understood.…”
Section: Introductionmentioning
confidence: 99%
“…Indeed sunitinib monotherapy doubles progression-free survival and extends overall survival in this disease and is now standard first-line therapy (Motzer et al, 2007(Motzer et al, , 2009. Despite these impressive results, variation in response between individuals occurs and, more importantly, resistance to therapy invariably develops (Motzer et al, 2009;Rini and Atkins, 2009). Determinants of sunitinib response and the mechanisms that mediate the onset of resistance to sunitinib are poorly understood.…”
Section: Introductionmentioning
confidence: 99%
“…In a phase III study in treatment-na€ ve patients with metastatic renal cell carcinoma (RCC), sunitinib significantly doubled median progression-free survival compared with IFN-a and extended median overall survival beyond 2 years (5,6). Sunitinib is approved for the first-line treatment of advanced or metastatic RCC and imatinib-resistant or imatinib-intolerant advanced gastrointestinal stromal tumors (GIST).…”
Section: Introductionmentioning
confidence: 99%
“…Many other drugs which could come under the umbrella of targeted therapy were approved in subsequent years (sorafenib, mTOR inhibitors, bevacizumab, pazopanib, axitinib and many others). These drugs showed improvement in the overall survival (OS), progression-free survival (PFS) and response rates as compared to immunotherapy [15][16][17][18]. With such a response, even concern has been raised about the delay in the treatment of TT caused by CRN.…”
Section: Resultsmentioning
confidence: 99%